-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3417 Low CD117 Expression Identifies Hematopoietic Stem Cell Subsets with Enhanced Lymphoid Potential in Mice and Humans

Program: Oral and Poster Abstracts
Session: 701. Experimental Transplantation: Basic and Translational: Poster II
Hematology Disease Topics & Pathways:
hematopoiesis, immunology, Biological Processes
Sunday, December 10, 2023, 6:00 PM-8:00 PM

Harold K Elias, MD1,2, Sneha Mitra, PhD3*, Brianna Gipson, BSc4*, Marina Burgos da Silva, PhD1*, Nicole Lee, BSc1*, Mohamed A.E. Ali, MBBS, MSc, PhD5*, Simon Grassman, MD PhD1*, Anastasia Kousa, PhD4*, Susan DeWolf, MD6, Christopher Y. Park, MD, PhD7, Joseph Sun, PhD1*, Christina Leslie, PhD8*, Avinash Bhandoola, MBBS PhD9* and Marcel R.M. van den Brink10,11

1Department of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York
2National Institutes of Health, Bethesda, MD
3Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York
4Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY
5Department of Pathology, New York University Grossman School of Medicine, New York
6Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York
7Department of Pathology, NYU Langone School of Medicine, New York
8Computational and Systems Biology,Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York
9NCI, NHGRI, National Institutes of Health, Bethesda
10Department of Immunology, Sloan Kettering Institute, New York, NY
11City of Hope, Los Angeles, CA

Background: Hematopoietic stem cells (HSCs) with multilineage potential are critical for effective de novo T-cell generation and thymic recovery, restoring the adaptive immune system after Hematopoietic Cell Transplantation (HCT). Recent studies have brought new insights into functional heterogeneity within HSCs, revealing an organized and predictable framework governing the adoption of lineage-restricted fates. However, the gene-regulatory networks underlying lymphoid determination and their conservation with aging in HSCs need to be elucidated. This study aims to comprehensively investigate the molecular profile of young and old HSCs and identify HSC subsets with multilineage transcriptional programs.

Results: We conducted single-cell multiomic RNA and ATAC sequencing of young and old HSCs defined by Lineage-CD34-CD48-CD150+Sca-1+Kit+. We identified two CD117 (Kit) HSC subsets, Kitlo and Kithi, with unique transcriptional profiles. Kithi HSCs were characterized by quiescence, platelet bias, and low-output gene signatures, while Kitlo HSCs enriched for multi-lineage and high-output gene signatures. We observed a decreased frequency of Kitlo HSCs in aged mice. Although Kitlo HSCs have been previously described to exhibit increased self-renewal (Shin et al. JEM, 2014), their T-cell potential and the molecular underpinnings governing lymphoid differentiation programs are unknown.

We performed in vitro studies, S17 stromal assay, and artificial thymic organoids (ATOs), which revealed an enhanced output of lymphoid progenitors and T-cells from Kitlo HSCs, consistent across all age cohorts. We next compared Kitlo vs. Kithi HSCs in a competitive allogeneic HCT model. Kitlo HSCs demonstrated improved thymic recovery and post-HCT T-cell reconstitution, independent of age. To orthogonally evaluate post-HCT thymic function, we assessed Recent Thymic Emigrants (RTEs) output, which further substantiated superior recovery in mice receiving Kitlo HSCs. We further observed that Kitlo HSC-derived T-cells exhibited better proliferation in response to an acute Listeria monocytogenes infection. Next, we transplanted middle-aged mice to evaluate the rejuvenation potential of different Kit HSC subsets. We observed that Kitlo HSCs partly mitigated age-related changes in the thymic microenvironment, specifically by enhancing the regeneration of thymic epithelial cells (TECs) in middle-aged mice, thereby reversing the decline in T-cell production.

We found differential expression and activity of key transcription factors (TFs), including Runx3, Zbtb7a, and Ezh1, associated with lymphoid differentiation through integrative transcriptional and chromatin accessibility analyses of Kitlo HSCs. These TFs notably showed distinct patterns in Kitlo HSCs independent of age, indicating their potential role in driving their enhanced T-cell potential.

To establish the existence of a comparable human subset, we interrogated a human BM CITE-Seq dataset (Sommarin et al. Biorxiv 2021) for the mouse Kitlo gene signature. In concordance with our findings in mice, we observed an enrichment of the Kitlo gene program in young HSCs and decreased frequency of Kitlo HSCs in old BM. Next, we used ATOs to validate differential lymphoid potential. We found increased T-cell output originating from Kitlo HSCs, thus underscoring their enhanced lymphoid capacity and potential clinical relevance.

Conclusion: Collectively, we demonstrate a distinct HSC subset, Kitlo HSC, with an age-conserved lymphoid gene program that enhances T-cell production and facilitates thymic regeneration. Importantly, we demonstrate the presence of an analogous HSC subset in humans, revealing the relevance of these insights to human health and disease. Thus, Kitlo HSCs have therapeutic potential to counteract age-associated immune senescence and treatment-related immune suppression.

Disclosures: Leslie: Episteme Prognostics,: Other: SAB member and co-inventor of IP. van den Brink: Seres Therapeutics: Consultancy, Current holder of stock options in a privately-held company, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: IP licensing , Research Funding; Rheos Medicines: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Frazier Healthcare Partners: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Nektar Therapeutics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Notch Therapeutics: Consultancy, Current holder of stock options in a privately-held company, Honoraria, Membership on an entity's Board of Directors or advisory committees; Ceramedix: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Lygenesis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Pluto Immunotherapeutics: Consultancy, Current holder of stock options in a privately-held company, Honoraria, Membership on an entity's Board of Directors or advisory committees; DKMS (a non-profit organization): Membership on an entity's Board of Directors or advisory committees; Juno Therapeutics: Other: IP licensing; Wolters Kluwer: Patents & Royalties; Vor Biopharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Da Volterra: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Thymofox: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH